ÐÇ¿Õ´«Ã½

Rodney R. Miles
No Rating Available
(Learn About Our Rating System)

Rodney R. Miles, MD, PhD

Languages spoken: English

Clinical Locations

ARUP

Hematopathology
Salt Lake City
801-581-5854

  • Dr. Miles is a Medical Director of Hematopathology at ARUP Laboratories and a Professor of Pathology at the University of Utah School of Medicine. Dr. Miles received his MD and a PhD in cell biology from the University of Nebraska. He is certified by the American Board of Pathology in anatomic and clinical pathology, with subspecialty certification in hematology. His research interests include pediatric non-Hodgkin lymphoma and acute lymphoblastic leukemia.

    Dr. Miles is a member of the American Society of Hematology, the Society for Hematopathology, and the United States and Canadian Academy of Pathology. He is a member of the Children's Oncology Group non-Hodgkin lymphoma committee and serves as a central pathology reviewer for clinical trials.

    Specialties

    Board Certification

    American Board of Pathology (Anatomic & Clinical)
    American Board of Pathology (Sub: Hematology)

  • Dr. Miles is a Medical Director of Hematopathology at ARUP Laboratories and a Professor of Pathology at the University of Utah School of Medicine. Dr. Miles received his MD and a PhD in cell biology from the University of Nebraska. He is certified by the American Board of Pathology in anatomic and clinical pathology, with subspecialty certification in hematology. His research interests include pediatric non-Hodgkin lymphoma and acute lymphoblastic leukemia.

    Dr. Miles is a member of the American Society of Hematology, the Society for Hematopathology, and the United States and Canadian Academy of Pathology. He is a member of the Children's Oncology Group non-Hodgkin lymphoma committee and serves as a central pathology reviewer for clinical trials.

    Board Certification and Academic Information

    Academic Departments Pathology -Primary
    Board Certification
    American Board of Pathology (Anatomic & Clinical)
    American Board of Pathology (Sub: Hematology)

    Education history

    Fellowship Hematopathology - University of Michigan Fellow
    Research Fellow Hematopathology - University of Michigan Research Fellow
    Chief Resident Pathology - University of Utah School of Medicine Chief Resident
    Residency Pathology - University of Utah School of Medicine Resident
    Doctoral Training Cell Biology - University of Nebraska Medical Center Ph.D.
    Professional Medical Medicine - University of Nebraska Medical Center M.D.
    Undergraduate Chemistry - Grinnell College B.A.

    Selected Publications

    Journal Article

    1. Guest EM, Kairalla JA, Devidas M, Hibbitts E, Carroll AJ, Heerema NA, Kubaney HR, August MA, Ramesh S, Yoo B, Farooqi MS, Pauly MG, Wechsler DS, Miles RR, Reid JM, Kihei CD, Gore L, Raetz EA, Hunger SP, Loh ML, Brown PA (2024). Azacitidine as epigenetic priming for chemotherapy is safe and well-tolerated in infants with newly diagnosed KMT2A-rearranged acute lymphoblastic leukemia: Children's Oncology Group trial AALL15P1. Haematologica. ()
    2. Hayashi RJ, Hermiston ML, Wood BL, Teachey DT, Devidas M, Chen Z, Annett RD, Asselin BL, August K, Cho S, Dunsmore KP, Freedman JL, Galardy PJ, Harker-Murray P, Horton TM, Jaju A, Lam A, Messinger YH, Miles RR, Okada M, Patel S, Schafer ES, Schechter T, Shimano KA, Singh N, Steele A, Sulis ML, Vargas SL, Winter SS, Wood C, Zweidler-McKay PA, Loh ML, Hunger SP, Raetz EA, Bollard CM, Allen CE (2024). MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children's Oncology Group trial AALL1231. Blood, 143(20), 2053-2058. ()
    3. Teachey DT, Devidas M, Wood BL, Chen Z, Hayashi RJ, Hermiston ML, Annett RD, Archer JH, Asselin BL, August KJ, Cho SY, Dunsmore KP, Fisher BT, Freedman JL, Galardy PJ, Harker-Murray P, Horton TM, Jaju AI, Lam A, Messinger YH, Miles RR, Okada M, Patel SI, Schafer ES, Schechter T, Singh N, Steele AC, Sulis ML, Vargas SL, Winter SS, Wood C, Zweidler-McKay P, Bollard CM, Loh ML, Hunger SP, Raetz EA (2022). Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma. J Clin Oncol, 40(19), 2106-2118. ()
    4. Underdown MJ, Miles RR, Gross TG, Winters AC (2021). Importance of clinical correlation in the diagnosis of pediatric B-cell lymphomas. Pediatr Blood Cancer, 69(3), e29527. ()
    5. Burke GAA, Minard-Colin V, Auprin A, Alexander S, Pillon M, Delgado R, Zsros J, Uyttebroeck A, Dartigues P, Miles RR, Kazanowska B, Chiang AK, Haouy S, Bollard CM, Csoka M, Wheatley K, Barkauskas DA, Adamson PC, Vassal G, Patte C, Gross TG (2021). Dose-Adjusted Etoposide, Doxorubicin, and Cyclophosphamide With Vincristine and Prednisone Plus Rituximab Therapy in Children and Adolescents With Primary Mediastinal B-Cell Lymphoma: A Multicenter Phase II Trial. J Clin Oncol, 39(33), 3716-3724. ()
    6. Li P, Venkatachalam S, Ospina Cardona D, Wilson L, Kovacsovics TJ, Moser KA, Miles RR, Beck DB, George TI, Tantravahi SK (2022). A clinical, histopathological, and molecular study of two cases of VEXAS syndrome without a definitive myeloid neoplasm. Blood Adv, 6(2), 405-9. ()
    7. Goldman S, Barth M, Shiramizu B, Shi Q, Hochberg J, Klejmont L, Harrison L, Basso J, Chu Y, Islam H, Gerard P, Agsalda-Garcia M, Shieh T, Oesterheld J, Heym K, Kirov I, Drachtman R, Harker-Murray P, Perkins S, Miles RR, Cairo M (2021). A dose substitution of anthracycline intensity with dose-dense rituximab in children and adolescents with good-risk mature B-cell lymphoma. Leukemia, 35(10), 2994-2997. ()
    8. Mangum DS, Meyer JA, Mason CC, Shams S, Maese LD, Gardiner JD, Downie JM, Pei D, Cheng C, Gleason A, Luo M, Pui CH, Aplenc R, Hunger SP, Loh M, Greaves M, Trede N, Raetz E, Frazer JK, Mullighan CG, Engel ME, Miles RR, Rabin KR, Schiffman JD (2022). Association of Combined Focal 22q11.22 Deletion and IKZF1 Alterations With Outcomes in Childhood Acute Lymphoblastic Leukemia. JAMA Oncol, 7(10), 1521-1528. ()
    9. Xu X, Paxton CN, Hayashi RJ, Dunsmore KP, Winter SS, Hunger SP, Winick NJ, Carroll WL, Loh ML, Devidas M, Gross TG, Bollard CM, Perkins SL, Miles RR (2021). Genomic and clinical characterization of early T-cell precursor lymphoblastic lymphoma. Blood Adv, 5(14), 2890-2900. ()
    10. Viola D, Dona A, Caserta E, Troadec E, Besi F, McDonald T, Ghoda L, Gunes EG, Sanchez JF, Khalife J, Martella M, Karanes C, Htut M, Wang X, Rosenzweig M, Chowdhury A, Sborov D, Miles RR, Yazaki PJ, Ebner T, Hofmeister CC, Forman SJ, Rosen ST, Marcucci G, Shively J, Keats JJ, Krishnan A, Pichiorri F (2021). Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting. Leukemia, 35(1), 189-200.
    11. Hayashi RJ, Winter SS, Dunsmore KP, Devidas M, Chen Z, Wood BL, Hermiston ML, Teachey DT, Perkins SL, Miles RR, Raetz EA, Loh ML, Winick NJ, Carroll WL, Hunger SP, Lim MS, Gross TG, Bollard CM (2020). Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children's Oncology Group AALL0434. J Clin Oncol, 38(26), 3062-3070. ()
    12. Minard-Colin V, Auprin A, Pillon M, Burke GAA, Barkauskas DA, Wheatley K, Delgado RF, Alexander S, Uyttebroeck A, Bollard CM, Zsiros J, Csoka M, Kazanowska B, Chiang AK, Miles RR, Wotherspoon A, Adamson PC, Vassal G, Patte C, Gross TG, European Intergroup for Childhood Non-Hodgkin Lymphoma, Childrens Oncology Group (2020). Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children. N Engl J Med, 382(23), 2207-2219. ()
    13. Radhakrishnan SV, Luetkens T, Scherer SD, Davis P, Vander Mause ER, Olson ML, Yousef S, Panse J, Abdiche Y, Li KD, Miles RR, Matsui W, Welm AL, Atanackovic D (2020). CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide. Nat Commun, 11(1), 798. ()
    14. Atanackovic D, Yousef S, Shorter C, Tantravahi SK, Steinbach M, Iglesias F, Sborov D, Radhakrishnan SV, Chiron M, Miles R, Salama M, Krger N, Luetkens T (Jan 2020). In vivo vaccination effect in multiple myeloma patients treated with the monoclonal antibody isatuximab. Leukemia, 34(1), 317-321.
    15. Panea RI, Love CL, Shingleton JR, Reddy A, Bailey JA, Moormann AM, Otieno JA, Ongecha JM, Oduor CI, Schroeder KMS, Masalu N, Chao NJ, Agajanian M, Major MB, Fedoriw Y, Richards KL, Rymkiewicz G, Miles RR, Alobeid B, Bhagat G, Flowers CR, Ondrejka SL, Hsi ED, Choi WWL, Au-Yeung RKH, Hartmann W, Lenz G, Meyerson H, Lin YY, Zhuang Y, Luftig MA, Waldrop A, Dave T, Thakkar D, Sahay H, Li G, Palus BC, Seshadri V, Kim SY, Gascoyne RD, Levy S, Mukhopadyay M, Dunson DB, Dave SS (2019). The whole-genome landscape of Burkitt lymphoma subtypes. Blood, 134(19), 1598-1607. ()
    16. Clark JJ, Hawkes JE, Florell SR, Miles RR, Wada DA (2019). Cutaneous T-Cell Acute Lymphoblastic Leukemia and the Expression Pattern of Terminal Deoxynucleotidyl Transferase Immunostaining in Mycosis Fungoides and Spongiotic Dermatitis. Dermatopathology (Basel), 6(3), 182-188. ()
    17. Chisholm KM, Mohlman J, Liew M, Termuhlen A, Cairo MS, Gross TG, Perkins SL, Miles RR (2019). IRF4 translocation status in pediatric follicular and diffuse large B-cell lymphoma patients enrolled in Children's Oncology Group trials. Pediatr Blood Cancer, 66(8), e27770. ()
    18. Jafek JL, Shakya A, Tai PY, Ibarra A, Kim H, Maddox J, Chumley J, Spangrude GJ, Miles RR, Kelley TW, Tantin D (2019). Transcription factor Oct1 protects against hematopoietic stress and promotes acute myeloid leukemia. Exp Hematol, 76, 38-48.e2. ()
    19. Galardy PJ, Bedekovics T, Macintyre E, Miles RR (2019). Lymphoma diagnostics: getting more from less. Br J Haematol, 185(6), 1136-1141. ()
    20. Patel AB, Miles RR, Deininger MW (2019). Lysozyme nephropathy in chronic myelomonocytic leukemia. Clin Case Rep, 7(6), 1263-1264. ()
    21. Yan D, Pomicter AD, Tantravahi S, Mason CC, Senina AV, Ahmann JM, Wang Q, Than H, Patel AB, Heaton WL, Eiring AM, Clair PM, Gantz KC, Redwine HM, Swierczek SI, Halverson BJ, Baloglu E, Shacham S, Khorashad JS, Kelley TW, Salama ME, Miles RR, Boucher KM, Prchal JT, OHare T, Deininger MW (2018). Nuclear-Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis. Clin Cancer Res, 25(7), 2323-2335. ()
    22. Pearson ADJ, Scobie N, Norga K, Ligas F, Chiodin D, Burke A, Minard-Colin V, Adamson P, Marshall LV, Balakumaran A, Benettaib B, Bhargava P, Bollard CM, Bolotin E, Bomken S, Buechner J, Burkhardt B, Caron H, Copland C, Demolis P, Egorov A, Farhan M, Zugmaier G, Gross T, Horton-Taylor D, Klapper W, Lesa G, Marcus R, Miles RR, Nottage K, Pacaud L, Ricafort R, Schrappe M, Sterba J, Vezan R, Weiner S, Kim SY, Reaman G, Vassal G (2019). ACCELERATE and European Medicine Agency Paediatric Strategy Forum for medicinal product development for mature B-cell malignancies in children. Eur J Cancer, 110, 74-85.
    23. Borga C, Park G, Foster C, Burroughs-Garcia J, Marchesin M, Shah R, Hasan A, Ahmed ST, Bresolin S, Batchelor L, Scordino T, Miles RR, Te Kronnie G, Regens JL, Frazer JK (2019). Simultaneous B and T cell acute lymphoblastic leukemias in zebrafish driven by transgenic MYC: implications for oncogenesis and lymphopoiesis. Leukemia, 33(2), 333-347. ()
    24. Elkeeb D, Hopkins Z, Miles RR, Halwani A, Wada D (2018). Ominous cutaneous presentation of acute myeloid leukemia without peripheral blood involvement upon initial presentation and relapse: case report and literature review. Eur J Dermatol, 28(6), 809-817. ()
    25. Zabriskie MS, Antelope O, Verma AR, Draper LR, Eide CA, Pomicter AD, Tran TH, Druker BJ, Tyner JW, Miles RR, Graham JM, Hwang JY, Varley KE, Toydemir RM, Deininger MW, Raetz EA, OHare T (2018). A novel AGGF1-PDGFRb fusion in pediatric T-cell acute lymphoblastic leukemia. Haematologica, 103(2), e87-e91. ()
    26. Bouska A, Bi C, Lone W, Zhang W, Kedwaii A, Heavican T, Lachel CM, Yu J, Ferro R, Eldorghamy N, Greiner TC, Vose J, Weisenburger DD, Gascoyne RD, Rosenwald A, Ott G, Campo E, Rimsza LM, Jaffe ES, Braziel RM, Siebert R, Miles RR, Dave S, Reddy A, Delabie J, Staudt LM, Song JY, McKeithan TW, Fu K, Green M, Chan WC, Iqbal J (2017). Adult high-grade B-cell lymphoma with Burkitt lymphoma signature: genomic features and potential therapeutic targets. Blood, 130(16), 1819-1831. ()
    27. Meyer JA, Zhou D, Mason CC, Downie JM, Rodic V, Abromowitch M, Wistinghausen B, Termuhlen AM, Angiolillo AL, Perkins SL, Lones MA, Barnette P, Schiffman JD, Miles RR (2016). Genomic characterization of pediatric B-lymphoblastic lymphoma and B-lymphoblastic leukemia using formalin-fixed tissues. Pediatr Blood Cancer, 64(7). ()
    28. Patel S, Mason CC, Glenn MJ, Paxton CN, South ST, Cessna MH, Asch J, Cobain EF, Bixby DL, Smith LB, Reshmi S, Gastier-Foster JM, Schiffman JD, Miles RR (2017). Genomic analysis of adult B-ALL identifies potential markers of shorter survival. Leuk Res, 56, 44-51. ()
    29. Modzelewska K, Boer EF, Mosbruger TL, Picard D, Anderson D, Miles RR, Kroll M, Oslund W, Pysher TJ, Schiffman JD, Jensen R, Jette CA, Huang A, Stewart RA (2016). MEK Inhibitors Reverse Growth of Embryonal Brain Tumors Derived from Oligoneural Precursor Cells. Cell Rep, 17(5), 1255-1264. ()
    30. Liew M, Rowe L, Clement PW, Miles RR, Salama ME (2016). Validation of break-apart and fusion MYC probes using a digital fluorescence in situ hybridization capture and imaging system. J Pathol Inform, 7, 20. ()
    31. Meznarich J, Miles R, Paxton CN, Afify Z (2016). Pediatric B-Cell Lymphoma With Lymphoblastic Morphology, TdT Expression, MYC Rearrangement, and Features Overlapping With Burkitt Lymphoma. Pediatr Blood Cancer, 63(5), 938-40. ()
    32. Luo C, Deng Z, Li L, Clayton F, Chen AL, Wei R, Miles R, Stephens DM, Glenn M, Wang X, Jensen PE, Chen X (2015). Association of rituximab with graphene oxide confers direct cytotoxicity for CD20-positive lymphoma cells. Oncotarget, 7(11), 12806-22. ()
    33. Sangle NA, Miles RR, Kelley TW, Perkins SL (2013). Aberrant expression of multiple T antigens: CD4, CD5, and CD8 on diffuse large B-cell lymphoma. Appl Immunohistochem Mol Morphol, 22(10), e45-8. ()
    34. Shi DS, Smith MC, Campbell RA, Zimmerman PW, Franks ZB, Kraemer BF, Machlus KR, Ling J, Kamba P, Schwertz H, Rowley JW, Miles RR, Liu ZJ, Sola-Visner M, Italiano JE Jr, Christensen H, Kahr WH, Li DY, Weyrich AS (2014). Proteasome function is required for platelet production. J Clin Invest, 124(9), 3757-66. ()
    35. Shi DS, Smith MC, Campbell RA, Zimmerman PW, Franks ZB, Kraemer BF, Machlus KR, Ling J, Kamba P, Schwertz H, Rowley JW, Miles RR, Liu ZJ, Sola-Visner M, Italiano JE Jr, Christensen H, Kahr WH, Li DY, Weyrich AS (7/25/2014). Proteasome function is required for platelet production. J Clin Invest, 124(9), 3757-3766.
    36. Ririe MR, Florell SR, Miles RR, Duffy KL (2014). Secondary diffuse large B-cell lymphoma after chemotherapy for acute myeloid leukemia: looking for the unexpected diagnosis. Am J Dermatopathol, 36(7), e125-8. ()
    37. Smock KJ, Agarwal AM, Lim MS, Tripp SR, Miles RR, Patel JL, Abromowitch M, Lones MA, Cairo MS, Perkins SL (2/27/2014). Expression of Notch1 and mTOR Pathway Proteins in Pediatric Lymphoblastic Lymphoma; A Children's Oncology Group Report. J Hematop, 7(1), 9-14.
    38. Mangum DS, Downie J, Mason CC, Jahromi MS, Joshi D, Rodic V, Mschen M, Meeker N, Trede N, Frazer JK, Zhou Y, Cheng C, Jeha S, Pui CH, Willman CL, Harvey RC, Hunger SP, Yang JJ, Barnette P, Mullighan CG, Miles RR, Schiffman JD (2014). VPREB1 deletions occur independent of lambda light chain rearrangement in childhood acute lymphoblastic leukemia. Leukemia, 28(1), 216-20.
    39. Zhou W, Yang Y, Xia J, Wang H, Salama ME, Xiong W, Xu H, Shetty S, Chen T, Zeng Z, Shi L, Zangari M, Miles R, Bearss D, Tricot G, Zhan F (01/14/2013). NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers. Cancer Cell, 23(1), 48-62.
    40. Love C, Sun Z, Jima D, Li G, Zhang J, Miles R, Richards KL, Dunphy CH, Choi WW, Srivastava G, Lugar PL, Rizzieri DA, Lagoo AS, Bernal-Mizrachi L, Mann KP, Flowers CR, Naresh KN, Evens AM, Chadburn A, Gordon LI, Czader MB, Gill JI, Hsi ED, Greenough A, Moffitt AB, McKinney M, Banerjee A, Grubor V, Levy S, Dunson DB, Dave SS (11/11/2012). The genetic landscape of mutations in Burkitt lymphoma. Nat Genet, 44(12), 1321-5.
    41. Leventaki V, Rodic V, Tripp SR, Bayerl MG, Perkins SL, Barnette P, Schiffman JD, Miles RR (2012). TP53 pathway analysis in paediatric Burkitt lymphoma reveals increased MDM4 expression as the only TP53 pathway abnormality detected in a subset of cases. Br J Haematol, 158(6), 763-71. ()
    42. Ridges S, Heaton WL, Joshi D, Choi H, Eiring A, Batchelor L, Choudhry P, Manos EJ, Sofla H, Sanati A, Welborn S, Agarwal A, Spangrude GJ, Miles RR, Cox JE, Frazer JK, Deininger M, Balan K, Sigman M, Mschen M, Perova T, Johnson R, Montpellier B, Guidos CJ, Jones DA, Trede NS (2012). Zebrafish screen identifies novel compound with selective toxicity against leukemia. Blood, 119(24), 5621-31. ()
    43. Miles RR, Arnold S, Cairo MS (2012). Risk factors and treatment of childhood and adolescent Burkitt lymphoma/leukaemia. Br J Haematol, 156(6), 730-43. ()
    44. Schiffman JD, Lorimer PD, Rodic V, Jahromi MS, Downie JM, Bayerl MG, Sanmann JN, Althof PA, Sanger WG, Barnette P, Perkins SL, Miles RR (2011). Genome wide copy number analysis of paediatric Burkitt lymphoma using formalin-fixed tissues reveals a subset with gain of chromosome 13q and corresponding miRNA over expression. Br J Haematol, 155(4), 477-86. ()
    45. Ho AK, Teman CJ, Smith GP, Nightingale DR, Miles RR (2011). Composite mantle cell and diffuse large B-cell lymphoma: report of two cases. Int J Surg Pathol, 19(5), 643-8. ()
    46. Miles RR, Afify Z, Yaish H, Perkins SL (2010). CD56-negative extranodal nasal type NK/T-cell lymphoma. Pediatr Blood Cancer, 55(1), 186-9. ()

    Case Report

    1. Laggis C, Miles R, Stephens DM, Duffy K, Bowen A, Wada D (2019). Cutaneous mantle cell lymphoma histomorphologically mimicking subcutaneous panniculitis-like T-cell lymphoma: Case report. J Cutan Pathol, 46(7), 538-541. ()

    Letter

    1. Ng DP, Miles RR, Andersen EF, Toydemir RM (2021). Flow Cytometry Is More Sensitive Than Fluorescence In Situ Hybridization for Detecting Minimal Residual Disease. [Letter to the editor]. Am J Clin Pathol, 156(4), 715-716. ()
    2. Laggis CW, Lamb A, Secrest AM, Ufkes N, Halwani AS, Tao R, Gaffney D, Miles RR, Florell SR, Wada D (2020). Favourable outcomes in folliculotropic mycosis fungoides after multimodality treatment in a single institution. [Letter to the editor]. J Eur Acad Dermatol Venereol, 35(1), e42-e45. ()
    3. Wada C, Glenn MJ, Hyde M, Powell DL, Miles RR, Duffy K, Florell SR, Wada DA (2014). Primary cutaneous follicle centre lymphoma presenting as diffuse facial erythema. [Letter to the editor]. J Eur Acad Dermatol Venereol, 29(4), 825-6. ()